Yumanity Therapeutics Inc. (YMTX) stock prices were down by 0.76% as of the market closing on October 8th 2021. This brought the price per share down to USD$9.17 at the end of the trading day. Subsequent premarket fluctuations have seen the stock surge by 6.87%, bringing it up to USD$9.80.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Solid Liquidity Position
YMTX stock announced a stellar liquidity position for the second quarter of fiscal 2021. The company reported cash, cash equivalents, and investments in the amount of USD$55.6 million as of June 30th 2021. This is comparable to a liquidity position of USD$85.3 million as of December 31st 2021. The year over year decrease was largely driven by spending on the clinical development of YTX-7739, as well as costs associated with being a public company. Also contributing to the yearly difference were certain one-time costs that are associated with the company’s reverse merger with Proteostasis Therapeutics. The company expects its liquidity position to fund sustained operations late into the third quarter of fiscal 2022.
YMTX Stocks R&D Costs
Research and development costs for the second quarter of fiscal 2021 came out to USD$7.3 million. This is up from the R&D costs of USD$3.9 million for the second quarter of fiscal 2020. The year over year increase is largely attributable to costs associated with YMTX stock’s YTX-7739 clinical program. Development of the company’s YTX-9184 preclinical program also contributed to the yearly difference, as did increased spending on early-stage discovery efforts.
Net Loss Breakdown
The second quarter of fiscal 2021 saw YMTX stock report a net loss in the amount of USD$10.5 million. This represents a net loss of USD$1.03 per basic and diluted share for the 2021 quarter. The second quarter of fiscal 2021 saw the company report a net loss of USD$7 million, which excluded the gain on extinguishment of Class B preferred units. This represents a net loss of USD$0.13 per basic and diluted share for the second quarter of fiscal 2021. The year over year increase was primarily driven by an increase in research and development costs as well as increased general and administrative expenses.
Future Outlook for YMTX Stock
YMTX stock reported a promising quarter, as evidenced by the strength of its financial reports for the second quarter of fiscal 2021. The company is keen to maintain the momentum it has generated through the upcoming quarters. Current and potential investors are hopeful that management will be able to effectively leverage the resources at their disposal. This is hoped to usher in a continued trajectory of success for the company.
